缺氧诱导因子脯氨酰羟化酶抑制剂治疗慢性肾脏病贫血的有效性：系统评价和荟萃分析。
Effectiveness of hypoxia-induced factor prolyl hydroxylase inhibitor for managing anemia in chronic kidney disease: a systematic review and meta-analysis.
机构信息
Department of Endocrine, Huzhou Hospital of Traditional Chinese Medicine Affiliated, Zhejiang University of Traditional Chinese Medicine, Huzhou, 313000, Zhejiang, China.
Department of Nephrology, Huzhou Hospital of Traditional Chinese Medicine Affiliated, Zhejiang University of Traditional Chinese Medicine, Huzhou, 313000, Zhejiang, China.
出版信息
Eur J Clin Pharmacol. 2021 Apr;77(4):491-507. doi: 10.1007/s00228-020-03037-1. Epub 2020 Nov 7.
PURPOSE
To meta-statistically compare the efficiency of hypoxia-induced factor prolyl hydroxylase inhibitor on hemoglobin, ferritin, hepcidin rate, and adverse events.
METHODS
A systematic identification of literature was performed according to PRISMA guidelines on 4 academic databases: MEDLINE, Scopus, EMBASE, and CENTRAL. A meta-analysis evaluating the influence of hypoxia-induced factors was performed for patients undergoing/not undergoing hemodialysis. The analysis evaluated the efficacy of hypoxia-induced factors on hemoglobin, ferritin, hepcidin rate, and the number of adverse events.
RESULTS
Out of 1052 records, 15 articles including 2045 patients (mean age 62.1 ± 5.4 years) were included in this review. The systematic review presents a 1a level of evidence supporting the use of hypoxia-induced factor for mediating anemia in patients with chronic kidney disease. The meta-analysis reveals medium to large beneficial effects of the hypoxia-induced factor on hemoglobin rate for patients receiving (0.72) and not receiving (1.04) hemodialysis. Moreover, the administration of hypoxia-induced factors was reported to reduce ferritin rate and the hepcidin rate, and the number of adverse events in patients with chronic kidney disease.
CONCLUSION
The current meta-analysis recommends the use of hypoxia-induced factor prolyl hydroxylase inhibitor for managing anemia in chronic kidney disease.
目的
荟萃分析缺氧诱导因子脯氨酰羟化酶抑制剂对血红蛋白、铁蛋白、hepcidin 率和不良事件的疗效。
方法
根据 PRISMA 指南，在 4 个学术数据库（MEDLINE、Scopus、EMBASE 和 CENTRAL）中进行了系统的文献检索。对接受/未接受血液透析的患者进行了缺氧诱导因子影响的荟萃分析。该分析评估了缺氧诱导因子对血红蛋白、铁蛋白、hepcidin 率和不良事件数量的影响。
结果
在 1052 条记录中，有 15 篇文章包括 2045 名患者（平均年龄 62.1±5.4 岁）被纳入本综述。系统评价提供了 1a 级证据，支持使用缺氧诱导因子来调节慢性肾脏病患者的贫血。荟萃分析显示，缺氧诱导因子对接受（0.72）和未接受（1.04）血液透析的患者的血红蛋白率有中等至较大的有益影响。此外，缺氧诱导因子的给药被报道可降低慢性肾脏病患者的铁蛋白率、hepcidin 率和不良事件的数量。
结论
目前的荟萃分析建议使用缺氧诱导因子脯氨酰羟化酶抑制剂来治疗慢性肾脏病患者的贫血。
Zotero 插件